文献速递血脂与心血管预防冠心病

前蛋白转化酶枯草溶菌素9抑制剂降低心血管结局的系统综述与荟萃分析

Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and meta-analysis.
PubMed 文献 · Heart · 2019-03-06

结果显示PCSK9抑制剂显著降低MACE风险16%、非致死性心肌梗死17%和任何卒中25%,证据质量中等;对全因死亡、心血管死亡、心力衰竭或不稳定型心绞痛无显著差异,证据质量低。

要点

  • PCSK9抑制剂降低MACE风险16%(RR 0.84),非致死性MI风险17%(RR 0.83),任何卒中风险25%(RR 0.75)。
  • 10年风险差异:MACE每1000例减少47例(基线286),非致死性MI减少35例(基线207),卒中减少16例(基线61)。
  • 全因死亡、心血管死亡、心力衰竭及不稳定型心绞痛未见显著差异,证据质量低。

核心结论

  • PCSK9抑制剂可显著降低MACE、非致死性心肌梗死和卒中风险。
  • 对全因死亡、心血管死亡、心力衰竭或不稳定型心绞痛无显著影响,证据质量低。

研究设计与样本

  • 研究对象为接受PCSK9抑制剂进行心血管疾病一级和/或二级预防或患有高胆固醇血症/高脂血症的患者。
  • 二分类变量采用随机效应模型合并相对危险度(RR)及95%CI。
  • 使用合并RR和对照组估计基线风险估算10年风险差异(RD)。
  • 采用GRADE评估证据质量。

主要发现

  • 与对照组相比,PCSK9抑制剂使MACE风险降低16%(RR 0.84;95%CI 0.79-0.89;RD:每1000例减少47例,基线风险286;95%CI 32-59例减少),证据质量中等。
  • 非致死性心肌梗死风险降低17%(RR 0.83;95%CI 0.74-0.93;RD:每1000例减少35例,基线207;95%CI 13-53例减少),证据质量中等。
  • 任何卒中风险降低25%(RR 0.75;95%CI 0.65-0.85;RD:每1000例减少16例,基线61;95%CI 9-21例减少),证据质量中等。
  • 全因死亡、心血管死亡、心力衰竭或不稳定型心绞痛在PCSK9抑制剂组与对照组间无显著差异,证据质量低。

临床怎么用

  • 对于心血管疾病一级和/或二级预防或高胆固醇血症/高脂血症患者,PCSK9抑制剂可考虑用于降低MACE、非致死性心肌梗死和卒中风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: To evaluate the effects of proprotein convertase subtilisin/kexin 9 (PCSK9) inhibitors on major adverse cardiovascular events (MACE). METHODS: Our systematic review included randomised controlled trials if they studied PCSK9 inhibitors in patients for primary and/or secondary prevention of cardiovascular diseases or with hypercholesterolaemia/hyperlipidaemia. Dichotomous variables from individual studies were pooled by relative risks (RR) and their 95% CIs using the random-effect model. Risk difference (RD) in the 10-year frame was also estimated using the pooled RR and the estimated baseline risk using the control group. Grading of Recommendation Assessment, Development and Evaluation was used to assess the quality of evidence. RESULTS: We included 54 trials with 97 910 patients in the analysis. Compared with controls, PCSK9 inhibitors significantly reduced the risk of MACE by 16% (RR, 0.84; 95% CI 0.79 to 0.89; RD: 47 fewer per 1000 vs 286 as the baseline risk; 95% CI 32 to 59 fewer), non-fatal myocardial infarction (MI) by 17% (RR, 0.83; 95% CI 0.74 to 0.93; RD, 35 fewer per 1000 vs 207 as the baseline; 95% CI 13 to 53 fewer) and any stroke by 25% (RR, 0.75; 95% CI 0.65 to 0.85; RD, 16 fewer per 1000 vs 61 as the baseline; 95% CI 9 to 21 fewer) with moderate quality evidence. No significant differences were found between PCSK9 inhibitors and control groups in all-cause mortality, cardiovascular death, heart failure or unstable angina with low-quality evidence. CONCLUSIONS: This study demonstrated that PCSK9 inhibitors could significantly reduce the risk of MACE, non-fatal MI and stroke. TRIAL REGISTRATION: PROSPERO; CRD42017073904.

来源:Heart,查看原文。版权归原作者所有。

引用

  1. Du H, Li X, Su N, et al. Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and meta-analysis. Heart. 2019. PMID: 30842207. doi:10.1136/heartjnl-2019-314763

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。